30 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) https://seekingalpha.com/article/4656759-teva-4-key-drivers-for-a-2024-revival-upgraded-rating?source=feed_tag_israel Dec 07, 2023 - Teva Pharmaceutical has a disciplined financial management and innovative product pipeline. Find out why TEVA stock is a Buy.
Corcept Therapeutics plunges after loss in patent battle with with Teva https://seekingalpha.com/news/4051439-corcept-therapeutics-plunges-after-loss-in-patent-battle-with-with-teva?source=feed_sector_healthcare Jan 01, 2024 - Corcept Therapeutics (CORT) tumbles 38% in after-hours trading following a patent trial loss to Teva (TEVA) over its Cushing's syndrome drug, Korlym.
Teva raised to Buy at Jefferies citing a positive setup ahead of 2024 outlook https://seekingalpha.com/news/4057313-teva-stock-raised-buy-jefferies?source=feed_tag_israel Jan 23, 2024 - Jefferies upgrades Teva Pharmaceutical (TEVA) to Buy from Hold ahead of the company's 2024 outlook citing multiple tailwinds to its business. Read more here.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html Jan 28, 2024 - Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
Teva upgraded to Overweight at Piper Sandler on multiple expansion https://seekingalpha.com/news/4065532-teva-stock-upgraded-piper-sandler-valuation?source=feed_tag_israel Feb 12, 2024 - Piper Sandler upgraded Teva Pharmaceutical (TEVA) to Overweight and raised its price target to $19 from $12 per share citing valuation. Read more here.
Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold.
Teva and Jiangsu announce partnership for distribution of AUSTEDO in China https://seekingalpha.com/news/4071489-teva-and-jiangsu-announce-partnership-for-distribution-of-austedo-in-china?source=feed_tag_israel Feb 26, 2024 - Teva Pharmaceutical and Jiangsu Nhwa forge a strategic partnership to enhance patient access to AUSTEDO, a drug for neurodegenerative and movement...
Teva Pharmaceutical Industries: Potential Outweighs Concerns https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy.
Teva stock trades in the green for seventh straight session https://seekingalpha.com/news/4084589-teva-on-track-for-seventh-straight-day-of-gains?source=feed_tag_israel Mar 27, 2024 - Teva Pharmaceutical (TEVA) shares are on the rise, gaining for the 7th consecutive day.
Teva analysis shows migraine drug as effective in obese patients as non-obese https://seekingalpha.com/news/4044016-teva-analysis-shows-migraine-drug-as-effective-in-obese-patients-as-non-obese?source=feed_sector_healthcare Dec 06, 2023 - Teva Pharmaceutical Industries (TEVA) said that its drug Ajovy was found to be as effective in reducing migraine attacks in obese patients as non-obese. Read more here.

Pages: 123

Page 1>